174 related articles for article (PubMed ID: 34918626)
21. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W; Deng T; Li S; Shu Y; Wu Y
BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
[TBL] [Abstract][Full Text] [Related]
23. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
24. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
[TBL] [Abstract][Full Text] [Related]
25. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
26. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital.
Regal RE; DePestel DD; VandenBussche HL
Pharmacotherapy; 2003 May; 23(5):618-24. PubMed ID: 12741436
[TBL] [Abstract][Full Text] [Related]
27. Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
Tai CH; Shao CH; Wang CC; Lin FJ; Wang JT; Wu CC
J Antimicrob Chemother; 2021 Jan; 76(2):499-506. PubMed ID: 33152760
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis.
Chiu CY; Sarwal A
Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109649
[No Abstract] [Full Text] [Related]
29. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Kobayashi R; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
J Microbiol Immunol Infect; 2018 Aug; 51(4):473-477. PubMed ID: 28690028
[TBL] [Abstract][Full Text] [Related]
30. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and safety of prolonged versus intermittent administration of antipseudomonal beta-lactam antibiotics in adults with severe acute infections: A meta-analysis of randomized controlled trials.
Kıran P; Nadir Y; Gencer S
J Infect Chemother; 2023 Sep; 29(9):855-862. PubMed ID: 37169223
[TBL] [Abstract][Full Text] [Related]
32. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
[TBL] [Abstract][Full Text] [Related]
33. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
[TBL] [Abstract][Full Text] [Related]
35. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
36. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
[TBL] [Abstract][Full Text] [Related]
37. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
[TBL] [Abstract][Full Text] [Related]
38. Piperacillin/tazobactam and risk of acute kidney injury in adults hospitalized with infection without vancomycin: a multi-centre real-world data analysis.
Su G; Xiao C; Cao Y; Gao P; Xie D; Cai Q; Nie S; Liu X; Lu F; Zhou Y; Hu Y; Li H; Yang Q; Wan Q; Liu B; Xu H; Li G; Weng J; Xu G; Chen C; Liu H; Shi Y; Zha Y; Kong Y; Tang Y; Shen J; Johnson DW; Xu X; Hou FF
Int J Antimicrob Agents; 2023 Jan; 61(1):106691. PubMed ID: 36372344
[TBL] [Abstract][Full Text] [Related]
39. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.
Ram R; Halavy Y; Amit O; Paran Y; Katchman E; Yachini B; Kor S; Avivi I; Ben-Ami R
Clin Infect Dis; 2018 Sep; 67(8):1153-1160. PubMed ID: 29608680
[TBL] [Abstract][Full Text] [Related]
40. [Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa].
Djordjević Z; Gajović O; Mijailović Z; Ilić A; Stolić R
Srp Arh Celok Lek; 2013; 141(9-10):640-7. PubMed ID: 24364227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
